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Background: A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we
investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-
pseudomonal species.
Methods: The relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14,
and 7 days prior to antibiotics, day 3 of treatment, the ﬁnal day of treatment, and 10–14 days afterwards, by T-RFLP proﬁling.
Results: Overall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-
antibiotic 51.0±36.0% increasing to 71.3±30.4% during antibiotic (ANOVA: F1,54=5.16; Pb0.027). Further, the number of non-pseudomonal
species detected fell; pre-antibiotic 6.0±3.3 decreasing to 3.7±3.3 during treatment (ANOVA: F1,66=5.11; Pb0.027).
Conclusions: Antibiotic treatment directed at P. aeruginosa has an additional signiﬁcant impact on non-pseudomonal, co-colonising species.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Antibiotics; Pulmonary exacerbation; Bacterial diversity; T-RFLP; Relative abundance1. Introduction
Pseudomonas aeruginosa is commonly cultured from the adult
CF lung and chronic infection with this organism is also associated
with reduced life expectancy [1]. In patients who are chronically
infected, P. aeruginosa is commonly the primary target for
antibiotic therapy in response to the onset of CF pulmonary
exacerbation (CFPE) [2]. In such cases, it is common practise to⁎ Corresponding author at: King's College London, Pharmaceutical Science
Division, Franklin–Wilkins Building, 150 Stamford Street, London, SE1 9NH,
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doi:10.1016/j.jcf.2012.05.008administer two anti-pseudomonal antibiotics with different modes
of action; for example, a β-lactam and aminoglycoside [2].
Whilst often referred to as anti-pseudomonal, antibiotics
such as ciprofloxacin, ceftazidime, and tobramycin, are broad
spectrum, capable of affecting a wide array of Gram positive
and Gram negative bacteria. This is potentially important given
the many other bacterial species have been reported in adult CF
lower airway secretions in addition to P. aeruginosa [3-10].
In the most part, this wider bacterial diversity has only come to
light with the recent application of culture-independent, molecular
profiling techniques that avoid the often substantial challenge
of growing bacteria in vitro. As such, with the exception of a
relatively small group of species recognised as CF pathogens, the
clinical significance of these species is not yet known. It has,by Elsevier B.V. All rights reserved.
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species are capable of altering the virulence of P. aeruginosa
[11,12]. As such, the impact of antibiotics used to target P.
aeruginosa infections on non-pseudomonal species might be a
contributory factor in treatment outcome.
The culture-independent approach of terminal restriction
fragment length polymorphism (T-RFLP) analysis has been
shown recently to be informative in tracking changes in the
presence or absence of species over periods of antibiotic treatment
[9]. By differentiating between bacterial species based on their
16S ribosomal RNA gene sequences, T-RFLP profiling allows
P. aeruginosa populations to be distinguished from populations
of other bacterial species present in the same sample, and their
relative abundances assessed. Such analysis alone cannot
however report accurately changes in relative bacterial population
sizes in response antibiotic treatment. This is because DNA
present in bacteria killed by action of antibiotics, or subsequently
released into the extracellular environment, will contribute to
the signal derived. To prevent this, a photochemical strategy of
pre-treating samples prior to DNA extraction with propidium
monoazide (PMA) can be used to limit signal to only that from
viable bacterial cells [13,14]. The principle is based on membrane
integrity as a common sign of viability: PMA does not enter cells
with intact membranes, whereas it readily does so in cells with
compromised membranes [15]. In this way, the combination of
sample pre-treatment and T-RFLP profiling allows shifts in the
relative abundance of viable bacteria from different species to be
determined.
Here, we applied such a strategy to the analysis of sputum
samples from twelve adult CF patients, prior to, during, and
following, antibiotic treatment for pulmonary exacerbation.
2. Materials and methods
2.1. Subjects and clinical samples
This study was undertaken with local ethical approval from
Southampton and South West Hampshire Research Ethics Com-
mittee (06/Q1704/26). Sputum samples were collected pro-
spectively from 14 adult CF subjects at Southampton GeneralTable 1
Patient information.
Subject Age Gender Genotype I Genotype II FEV1 (% predicted)
1 30 Male phe508del Unknown 54.9
2 45 Female phe508del phe508del 40.2
3 30 Female phe508del 711+3A7G 38.2
4 22 Female phe508del phe508del 36.2
5 55 Male phe508del G85E 52.2
6 21 Female phe508del phe508del 56.6
7 22 Male phe508del phe508del 16.5
8 18 Female phe508del phe508del 84
9 24 Female phe508del G542X 72.5
10 20 Male phe508del phe508del 26.8
11 20 Male phe508del phe508del 54.4
12 23 Male phe508del phe508del 53.6Hospital, Southampton, UK. Subjects were selected that were
persistently productive of sputum. All subjects provided sputum
samples and clinical monitoring information three times per week
for at least 12 months.
All subjects had a previous history of CFPE. During the
study period only 12 of 14 patients experienced at least one
exacerbation, and only data from these are presented. The start
of a CFPE was defined by the clinician's decision to initiate
antibiotic therapy for deteriorating clinical status, broadly based
on a range of factors described previously [17]. In turn, the end
of CFPE was defined by the decision to cease antibiotic therapy
due to stabilisation or improvement in signs and symptoms.
Clinical information and details of antibiotic treatment
given during CFPE for these twelve patients are shown in
Table 1. A range of antibiotic selections was administered. In
addition to antibiotics selected as anti-pseudomonal treatments
(ciprofloxacin, colomycin, tobramycin, meropenem, amikacin,
gentamicin), antibiotics used included those that potentially would
be active against P. aeruginosa, but which were not selected for
their anti-pseudomonal properties (doxycycline - Patient 3, and
clarithromycin - Patient 9), and agents that would not be expected
to have an anti-pseudomonal impact (metronidazole, used in
conjunction with ciprofloxacin – Patient 10).
Samples were selected retrospectively for analysis that fell
approximately 21, 14, 7 days prior to the start of antibiotic
treatment for pulmonary exacerbation, and then at day 3 of
treatment, on the final day of treatment, and 10–14 days after the
end of treatment.2.2. Clinical assessment
Prospective monitoring of clinically relevant symptoms and
spirometry was undertaken at the time of each sputum sample.
Lung function (FEV1) was assessed using a Koko PeakPro home
spirometer (Ferraris Cardiorespiratory, Louisville, CO, USA). In
addition, four respiratory symptoms were measured using visual
analogue scales (VAS), with patients asked to assess levels of
breathlessness, cough, sputum production, and general well-being,
scored from 0 to 100, representing worst and best respectively.BMI Diabetic Antibiotics given for CFPE
29 No Ciprofloxacin PO
18.5 Yes Colomycin IV+tobramycin IV
25 No Doxycycline PO
19 No Ciprofloxacin PO, then meropenem IV+amikacin IV
24.5 No Ceftazidime IV+gentamicin IV
19 No Ciprofloxacin PO
17.9 Yes Meropenem IV+colomycin IV
22.5 No Ceftazidime IV+gentamycin IV
23.4 No Clarithromycin PO
30.4 No Ciprofloxacin PO+metronidazole PO
21 No Ceftazidime IV+gentamycin IV
20.7 Yes Meropenem IV+tobramycin IV
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Samples were refrigerated immediately on collection. A portion
of all samples was aseptically removed and submitted for routine
CF microbiological assessment at the Health Protection Agency
South East laboratory, in accordance with Health Protection
Agency standard operating procedures [16]. Samples were then
frozen prior to processing and transported by courier in accordance
with national guidelines [2,16].
2.4. Propidium monoazide cross-linking
Propidium monoazide (PMA) treatment was performed as
described previously [18]. Specifically, PMA was dissolved in
20% dimethyl sulfoxide to create a stock concentration of
20 mmol/Lwith this added to samples to give a final concentration
of 50 μmol/L. Following an incubation period of 30 min in the
dark with occasional mixing, samples were light exposed using
LED Active Blue equipment (IB—Applied Science, Barcelona,
Spain).
2.5. DNA extraction, PCR amplification, and T-RFLP profile
analysis
Nucleic acid extractions were performed on 250 μL portions of
PMA-treated sputum. Guanidium thiocyanate–EDTA–sarkosyl
(500 μL) and phosphate buffered saline, pH 8.0 (500 μL) were
added to samples. Cell disruptionwas performed using a Fastprep-
24 instrument (MP Biomedicals Europe, Illkirch, France) at
6.5 m/s for 60 s, followed by incubation at 90 °C for 1 min and −
20 °C for 5 min. Cell debris was pelleted by centrifugation at
12,000g for 2 min at 4 °C. Precipitation of DNA from supernatant
was achieved by the addition of NaCl (to a final concentration of
0.5 mol/L) and polyethylene glycol (to a final concentration of
15% v/v), with incubation at 4 °C, for 30 min. DNA was pelleted
by centrifugation at 12,000g at 4 °C for 2 min and resuspended in
300 μL of sterile distilled water. Samples were heated at 90 °C for
30 s and vortexed. Next, 0.3 mL of Tris-buffered phenol (pH 8.0)
was added to each sample before the tubes were vortexed
vigorously. After centrifugation at 12,000g for 10 min, superna-
tants were transferred to fresh microcentrifuge tubes. A further
0.3 mL of Tris-buffered phenol (pH 8.0)–chloroform–isoamyl
alcohol (25:24:1) was added, and the mixture was vortexed
vigorously. After centrifugation at 12,000g for 10 min, DNA was
precipitated by the addition of an equal volume of isopropanol, a
0.1 volume of 10 M ammonium acetate, and 1 μLGenElute linear
polyacrylamide (Sigma–Aldrich, Gillingham, UK), with incuba-
tion at −20 °C for 1 h. DNA was pelleted by centrifugation at 12
000g for 5 min and washed three times in 70% ethanol. Pellets
were air dried and resuspended in 50 μL sterile distilled water.
DNA extracts were quantified using a Picodrop Microlitre
Spectrophotometer (GRI, Braintree, UK).
16S rRNA gene amplification was performed using the
universal oligonucleotide primers, 8f700IR (5′-700IR-AGAGT
TTGATCCTGGCTCAG-3′) and 926r (5′-CCGTCAATTCATTT
GAGTTT-3′) as described previously [3]. The constituents of the
PCR reaction mixture were as follows: 25 μL of Sigma readymixREDTaq (Sigma–Aldrich), each primer at a final concentration
of 0.2 μM, 50 ng of DNA template, made up to a final reaction
volume of 50 μL with nuclease-free water. Cycling conditions
comprised an initial denaturation at 94 °C for 2 min, followed by
32 cycles of denaturation at 94 for 1 min, annealing at 56 °C for
1 min, and extension at 72 °C for 2 min, with a final extension
step at 72 °C for 10 min.
Approximately 20 ng of each PCR product was digested to
completionwith 1 U of the restriction endonucleaseCfoI (Sigma–
Aldrich) for 5 h at 37 °C. Approximately 10 ng of digested PCR
product was denatured at 95 °C for 1 min and separated by
length using a 25 cm SequagelXR denaturing polyacrylamide
gel (National Diagnostics, Hessle, UK), containing 8.3 M urea
and formamide 10% v/v. Electrophoresis was performed at
55 °C and 1,200 V on an IR2 automated DNA sequencer (LI-
COR Biosciences, Lincoln, US).
T-RF band lengths and volumes were determined by com-
parison to marker microSTEP 15a (700 nm) (Microzone, Lewes,
UK) using Phoretix one-dimensional advances software (version
5.10; Nonlinear Dynamics, Newcastle upon Tyne, UK). T-RF
band volume was expressed as a percentage of the total band lane
volume. The resolution of T-RFLP bands was over the region of
50 to 950 bases, with a detection threshold of 0.1% of total profile
signal.
Each of the 72 samples collected was analysed by T-RFLP
profiling. The number of T-RF bands detected in each sample
(species richness), and their relative abundance, was determined.
Further, the relative proportions of all profiles that represented T-
RF bands derived from P. aeruginosa (defined as those of 155
bases) and T-RF bands from other species, were calculated.
2.6. Statistical analysis
One-wayANOVA tests (including,F-ratio, degrees of freedom,
and significance (P)) and summary statistics were calculated using
Minitab software (version 14.20, Minitab, USA).
3. Results
Results of routine diagnostic microbiology for the period
preceding CFPE are shown in Table 2. The presence of P.
aeruginosa in all subjects was confirmed by PCR, as described in
a previous study involving the same patient group [19].
Spirometry data for the patient group are shown in Fig. 1a. A
general trend of decreasing FEV1 from baseline values was
observed in the period prior to the start of antibiotic treatment,
with FEV1 recovery to pre-treatment levels observed in response
to therapy, and extending beyond its cessation. In keeping with
observed FEV1 data, summed VAS symptom scores increased in
the period prior to the initiation of antibiotic therapy, and
decreased in the period during, and following treatment (Fig. 1b).
T-RFLP profiling was performed on all sputum samples
following PMA treatment. Mean species richness for each
subject ranged from 1.2 to 9.0 species, with a mean richness for
the sample set as a whole of 5.5 species (SD 3.5 species). T-
RFLP profiles showed relative levels of P. aeruginosa to be
highly variable between individual subjects (Supplementary
Table 2
Conventional diagnostic microbial. Scant growth is denoted by “+,” moderate growth by “++” and heavy growth by “+++.”
Subject Culture 1 Culture 2 Culture 3 Culture 4
1 Pseudomonas spp. (++) Oral flora (+)
2 P. aeruginosa (+++) Pseudomonas spp. (+++) Oral flora (++) A. fumigatus (+++)
3 P. aeruginosa (+++) MRSA (S. aureus) (+) Oral flora (+++)
4 Pseudomonas spp. (+++) Oral flora (+++) P. aeruginosa mucoid (+++) A. fumigatus (+++)
5 Pseudomonas spp. (+++) Yeasts (+) Oral flora (+++) P. aeruginosa (+++)
6 P. aeruginosa (+++) Mucoid P. aeruginosa (+++)
7 Pseudomonas spp. (+++) Pseudomonas spp. (+++) Pseudomonas spp. (+++) Oral flora (+++)
8 Pseudomonas spp. (+++) Oral flora (+++) Yeasts (+) A. fumigatus (+)
9 P. aeruginosa (+++) Pseudomonas spp. (+++) Yeasts (+) A. fumigatus (+)
10 Pseudomonas spp. (+++) Pseudomonas spp. (+++) Pseudomonas spp. (+++) Oral flora (+++)
11 mucoid P. aeruginosa (+++) Pseudomonas spp. (+++)
12 Pseudomonas spp. (+++) Pseudomonas spp. (+++) Oral flora (+++)
Fig. 1. The (A) relative change in forced expiratory volume in the first second
(FEV1), and (B) summed VAS scores, before during and following initiation of
treatment for cystic fibrosis pulmonary exacerbation (CFPE) in twelve subjects.
Error bars represent 95% confidence interval around the median.
25T.W.V. Daniels et al. / Journal of Cystic Fibrosis 12 (2013) 22–28Fig. 1a). However, when pre- and during mean percentage relative
abundance of P. aeruginosa was compared within individual
subjects, only one subject (Patient 5), displayed a decrease in
relative abundance following initiation of antibiotic treatment
(Supplementary Fig. 1b). In addition, bacterial taxa richness
(excluding P. aeruginosa) was also highly variable between
subjects (Supplementary Fig. 1b). However, within individual
subjects, only subject (Patient 8) showed an increase in bacterial
richness following antibiotics. The overall pattern observed was a
decrease in mean richness of bacterial taxa detected during
treatment (Supplementary Fig. 1b). For illustrative purposes, an
example of changes observed in relative T-RF band intensity over
the six time points from one patient (Patient 9) is shown in
Supplementary Fig. 2.
When the patient group was analysed as a whole, the
abundance of P. aeruginosa relative to non-pseudomonal species
was seen to increase as a result of antibiotic therapy (Fig. 2a).
Whilst the difference in relative P. aeruginosa abundance was
not significant at any one time-point (ANOVA: F5,50=1.02;
P=0.413), the increase in relative abundance was significant
during antibiotic therapy when compared to the pre-treatment
period (ANOVA: F1,54=5.16; Pb0.027); where the mean
abundance pre- was 51.0±36.0% increasing to 71.3 ±30.4%
during treatment (Fig. 3a). Further, the overall mean bacterial
taxa richness was observed to decrease after the initiation of
antibiotic therapy treatment (Fig. 2b). Again, no single time point
showed a significant difference in mean bacterial taxa richness
(Fig. 2b) (ANOVA: F5,62=0.99; P=0.431); however, the
decrease in richness was significant when the overall pre-
treatment and during treatment data were compared (ANOVA:
F1,66=5.11; Pb0.027), where mean richness pre-treatment was
6.0±3.3 decreasing to 3.7±3.3 during treatment (Fig. 3b).
4. Discussion
Antibiotic therapy for pulmonary exacerbations in CF is
associated with both positive clinical outcomes [20-22] and a
reduction in the number of viable bacteria present in airway
secretions [14]. However, the possibility that the beneficial
effects that result from antibiotic therapy are contributed to by
their impact on species other than those being targeted, has
been raised [23]. These non-targeted bacteria represent a widearray of species, and commonly include facultative and obligate
anaerobes more traditionally associated with the oral cavity [3-
10].
Our aim was to investigate the relative impact of antibiotics
on P. aeruginosa and non-pseudomonal species in patients
during treatment for pulmonary exacerbation. In most cases,
where patients are chronically infected with P. aeruginosa,
antibiotics tend to be selected for their anti-pseudomonal
activity. It might be expected therefore that a greater impact
would be observed on P. aeruginosa populations as compared
to populations of other, non-pseudomonal species that are
Fig. 2. The (A) mean relative abundance (%) of Pseudomonas aeruginosa and
(B) mean bacterial taxa richness (excluding P. aeruginosa) over the time series.
Open circles denote pre-IV treatment and closed circles denote during/post IV
treatment. Error bars represent the standard deviation of the mean (n=12). Fig. 3. The (A) mean relative abundance (%) of Pseudomonas aeruginosa and
(B) mean bacterial taxa richness (excluding P. aeruginosa) pre- and during IV
treatment. Error bars represent the standard deviation of the mean (n=36).
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the relative abundance of P. aeruginosa would be seen. Further,
given that in most cases, eradication of P. aeruginosa is not
realistic in chronically infected adult patients, it is likely that there
would be little change in the number of species detected.
However, in contrast to such expectations, the analysis performed
here suggests that the opposite is true (when the patient group is
considered as a whole). Instead, an increase in the relative
abundance of P. aeruginosawas observed, with a decrease in the
total number of species detected.
An explanation for this observation is that, whilst absolute
numbers of both P. aeruginosa and non-pseudomonal species
decrease as a result of antibiotic therapy, the relative decrease in
non-pseudomonal numbers is greater. In turn, this leads to an
increase in relative P. aeruginosa abundance. Further, the
reduction in viable non-pseudomonal bacterial numbers results
in fewer species being detected, and hence a decline in species
richness.
These findings are not without precedent. Using standard,
selective cultures, anti-pseudomonal antibiotics have been shown
to have more significant antimicrobial effects on Haemophilus
influenzae than on P. aeruginosa in vivo [24]. T-RFLP has been
used previously to investigate the impact of antibiotic therapy on
bacterial community composition during CFPE. However,
Tunney et al. reported little impact on overall bacterial diversity
using such an approach, in contrast to the findings set out here[9]. A likely reason for this discrepancy is the effect of the steps
taken here to limit the contribution of DNA from dead bacterial
cells, namely PMA treatment of samples prior to DNA extraction.
The contribution of DNA in non-viable bacterial cells an in the
extracellular matrix has been shown previously to contribute
significantly to amplifiable DNA from CF sputum [13,14]. We
recognise that any delay in processing a sample following
expectoration may lead to a decrease in its viable bacterial
content. This is particularly true of anaerobic species and is most
marked in the hour immediately following collection (data not
shown). However, by employing a consistent sample handling
schedule here, any such impact would have been constant across
the sample set, and as such, could not explain the findings that we
report.
The explanation for the reported observations set out above is
supported by the fact that P. aeruginosa has a naturally high
tolerance of antibiotics compared to many other species [25]. It is,
for example, able to secrete a protective exopolysaccharide matrix,
grow as micro-aggregates or biofilms that confer protection
against antibiotics [26], and form sub-populations of “persister”
cells that are highly antibiotic tolerant [27]. In addition, P.
aeruginosa is able to adapt phenotypically to antibiotic exposure
to become more even more resistant, for example, by antibiotic-
mediated up-regulation of cyclic-di-GMP levels [28] and alginate
synthesis [29,30]. Further, hypermutable forms of P. aeruginosa
27T.W.V. Daniels et al. / Journal of Cystic Fibrosis 12 (2013) 22–28are common in CF lung infections [31], a factor that increases the
likelihood of strains developing resistance, particularly given the
protracted periods for which they colonise the CF airways, and
their repeated exposure to antibiotics.
It should be noted that an increase in the abundance of P.
aeruginosa relative to non-pseudomonal species and a decrease
in total bacterial richness were not observed for all patients. The
relative impact of antibiotic treatment on these two groups will
depend on a number of factors, including the level of antibiotic
resistance and antibiotic tolerance exhibited by the P. aeruginosa
strain(s) present in the patient's airways, the non-pseudomonal
species that are present and their susceptibility to the antibiotics,
type of antibiotics administered, and the patient's treatment
history. However, the periods of treatment studied here were not
selected on the basis of the antibiotics used, but were instead a
random sample from the wider patient group. As such, the
phenomenon of increasing relative P. aeruginosa abundance and
decreasing bacterial richness might be a widespread consequence
of antibiotic therapy for CFPE as commonly administered.
A reduction in the wider bacterial diversity relative to P.
aeruginosa in the CF airways as a result of antibiotic therapy may
not be of clinical significance, and may only represent a side-
effect of therapy whose primary benefit is derived from its direct
impact on P. aeruginosa. However, sufficient evidence of the
modulation of P. aeruginosa virulence by non-pseudomonal
species exists that the possible contribution of such an effect to
the beneficial impact of antibiotic therapy cannot be discounted.
As such, further investigation of whether a direct relationship
exists is now warranted.
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